Liu Yang

Liu Yang

Auto-generated profile, based on publicly available information

Liu Yang

Department of Neurology, Emergency Medical Center of Chongqing, Chongqing 400014, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2020 in Journal of Chemistry
Verified
Journal Article
Open access
PDF file
NLNing Li
Ning Li
YWYan Wang
Yan Wang
WLWensheng Li
Wensheng Li
HLHaiyan Li
Haiyan Li
LYLiu Yang
Liu Yang
Ibrahim. H. EissaIbrahim. H. Eissa
Ibrahim. H. Eissa
In the last few decades, Alzheimer’s disease (AD) has emerged as a serious global problem, and it has been considered as the most common type of dementia. PPARγ and beta-secretase 1 (BACE1) are considered as potential targets for Alzheimer’s disease management. In the same time, sulfonylureas and sulfonamides have been confirmed to have PPARγ agonistic activity. Aiming to obtain new anti-AD agents, thirty-five compounds of sulfonamide and sulfonylurea derivatives having the same essential pharmacophoric features of the reported PPARγ agonists have been subjected to virtual screening. Docking studies revealed that five compounds (1, 2, 3, 4, and 5) have promising affinities to PPARγ. They were also docked into the binding site of BACE1. In addition, ADMET and physicochemical properties of these compounds were considered. Additionally, these compounds were further evaluated against BACE1 and PPARγ. Compound 2 showed IC50 value of 1.64 μM against BACE1 and EC50 value of 0.289 μM against PPARγ.